Relay Therapeutics Inc [RLAY] stock prices are up 5.58% to $4.92 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The RLAY shares have gain 13.23% over the last week, with a monthly amount glided 17.14%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Relay Therapeutics Inc [NASDAQ: RLAY] stock has seen the most recent analyst activity on September 10, 2024, when Jefferies upgraded its rating to a Buy and also boosted its price target to $16 from $10.60. On September 10, 2024, downgrade downgraded it’s rating to Perform. Barclays upgraded its rating to a Overweight but stick to its price target of $15 on May 10, 2024. Jefferies upgraded its rating to a Hold but $12.50 remained the price target by the analyst firm on April 20, 2023. Raymond James upgraded its rating to Strong Buy for this stock on April 19, 2023, but kept the price target unchanged to $29. In a note dated April 13, 2023, Raymond James initiated an Outperform rating and provided a target price of $29 on this stock.
The stock price of Relay Therapeutics Inc [RLAY] has been fluctuating between $3.50 and $11.16 over the past year. Currently, Wall Street analysts expect the stock to reach $18 within the next 12 months. Relay Therapeutics Inc [NASDAQ: RLAY] shares were valued at $4.92 at the most recent close of the market. An investor can expect a potential return of 265.85% based on the average RLAY price forecast.
Analyzing the RLAY fundamentals
The Relay Therapeutics Inc [NASDAQ:RLAY] reported sales of 10.01M for trailing twelve months, representing a drop of -100.00%. Gross Profit Margin for this corporation currently stands at 0.59% with Operating Profit Margin at -39.27%, Pretax Profit Margin comes in at -34.5%, and Net Profit Margin reading is -34.5%. To continue investigating profitability, this company’s Return on Assets is posted at -0.37, Equity is -0.46 and Total Capital is -0.44. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.68 points at the first support level, and at 4.45 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.10, and for the 2nd resistance point, it is at 5.29.
Ratios To Look Out For
It’s worth pointing out that Relay Therapeutics Inc [NASDAQ:RLAY]’s Current Ratio is 18.42. Also, the Quick Ratio is 18.42, while the Cash Ratio stands at 3.24. Considering the valuation of this stock, the price to sales ratio is 82.27, the price to book ratio is 0.98.
Transactions by insiders
Recent insider trading involved THE PATEL FAMILY IRREVOCABLE U, Officer, that happened on Jan 22 ’25 when 0.12 million shares were purchased. Officer, THE PATEL FAMILY IRREVOCABLE U completed a deal on Jan 21 ’25 to buy 0.12 million shares. Meanwhile, Rahmer Peter sold 32177.0 shares on Jan 03 ’25.
